Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1748-1716.1960.tb00072.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preparation and Characterization of a Novel Magnetic Molecularly Imprinted Polymer Capable of Isolating and Purifying Cordycepin from a Submerged Culture of the Caterpillar Medicinal Mushroom Cordyceps militaris (Ascomycetes).
Int J Med Mushrooms
December 2024
School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, People's Republic of China; Shandong Provincial Collaborative Innovation Center for Quality Control and Construction of the Whole Industrial Chain of Traditional Chinese Medicine, Jinan, Shandong, 250355, People's Republic of China.
In this work, magnetic molecularly imprinted polymer (MMIP) capable of selectively recognizing and adsorbing cordycepin was prepared. The MMIP was prepared using cordycepin as the template molecule, methacrylic acid and acrylamide as the functional monomer and ethylene glycol dimethacrylate as the crosslinker. The MMIP was analyzed using various techniques including transmission electron microscopy, thermogravimetric analysis, Fourier transform infrared spectroscopy, vibrating sample magnetometer and x-ray diffraction.
View Article and Find Full Text PDFTargeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis.
Immunol Res
December 2024
Department of Neurology, Center for Translational Neuro- and Behavioural Sciences, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
The inhibition of the neonatal Fc receptor (FcRn) is a promising therapeutic pathway in certain autoimmune disorders to reduce the amount of circulating pathogenic IgG autoantibodies by interfering with their recycling system. FcRn antibodies are currently being tested in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This study aimed to investigate the therapeutic potential of an antibody targeting FcRn in the intracellular adhesion molecule 1 (ICAM1)-deficient NOD mouse-a model representative for many aspects of human CIDP.
View Article and Find Full Text PDFBeyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.
Int J Mol Sci
October 2024
Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka 565-0871, Japan.
The advent of recycling antibodies, leveraging pH-dependent antigen binding and optimized FcRn interaction, has advanced the field of antibody therapies, enabling extended durability and reduced dosages. Eculizumab (Soliris) demonstrated the efficacy of C5 inhibitors for paroxysmal nocturnal hemoglobinuria (PNH), while its derivative, ravulizumab (Ultomiris), recognized as a recycling antibody, extended the dosing intervals. However, limitations including intravenous administration and inefficacy in patients with the R885H single-nucleotide polymorphism (SNP) in C5 could necessitate alternative solutions.
View Article and Find Full Text PDFSubcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
Neurotherapeutics
September 2024
Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.
ADAPT-SC (NCT04735432) was designed to evaluate noninferiority of subcutaneous (SC) efgartigimod PH20 to intravenous (IV) efgartigimod in participants with generalized myasthenia gravis (gMG). ADAPT-SC+ (NCT04818671) is an open-label extension study designed to assess long-term safety, tolerability, and efficacy of efgartigimod PH20 SC. Adult participants in ADAPT-SC were randomly assigned to receive a treatment cycle of 4 once-weekly administrations of efgartigimod PH20 SC 1000 mg or efgartigimod IV 10 mg/kg, followed by 7 weeks of follow-up.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!